+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease



Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease



American Journal of the Medical Sciences 348(2): 108-114



Statins reduce the risk of coronary heart disease (CHD) in individuals with a history of CHD or risk equivalents. A 10-year CHD risk >20% is considered a risk equivalent but is frequently not detected. Statin use and low-density lipoprotein cholesterol (LDL-C) control were examined among participants with CHD or risk equivalents in the nationwide Reasons for Geographic and Racial Differences in Stroke study (n = 8812). Participants were categorized into 4 mutually exclusive groups: (1) history of CHD (n = 4025); (2) no history of CHD but with a history of stroke and/or abdominal aortic aneurysm (AAA) (n = 946); (3) no history of CHD or stroke/AAA but with diabetes mellitus (n = 3134); or (4) no history of the conditions in (1) through (3) but with 10-year Framingham CHD risk score (FRS) >20% calculated using the third Adult Treatment Panel point scoring system (n = 707). Statins were used by 58.4% of those in the CHD group and 41.7%, 40.4% and 20.1% of those in the stroke/AAA, diabetes mellitus and FRS >20% groups, respectively. Among those taking statins, 65.1% had LDL-C <100 mg/dL, with no difference between the CHD, stroke/AAA, or diabetes mellitus groups. However, compared with those in the CHD group, LDL-C <100 mg/dL was less common among participants in the FRS >20% group (multivariable adjusted prevalence ratio: 0.72; 95% confidence interval: 0.62-0.85). Results were similar using the 2013 American College of Cardiology/American Heart Association cholesterol treatment guideline. These data suggest that many people with high CHD risk, especially those with an FRS >20%, do not receive guideline-concordant lipid-lowering therapy and do not achieve an LDL-C <100 mg/dL.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911365

Download citation: RISBibTeXText

PMID: 24892511

DOI: 10.1097/MAJ.0000000000000292


Related references

High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency. Journal of Endocrinological Investigation 34(1): 32-37, 2011

From the Centers for Disease Control and Prevention. Prevalence of adults with no known major risk factors for coronary heart disease--Behavioral Risk Factor Surveillance System, 1992. JAMA 271(10): 741-742, 1994

Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. British Journal of Clinical Pharmacology 58(5): 528-535, 2004

Prevalence of coronary heart disease risk factors and screening for high cholesterol levels among young adults, United States, 1999-2006. Annals of Family Medicine 8(4): 327-333, 2011

Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. Current Atherosclerosis Reports 7(1): 22-28, 2005

Prediction of 10-year risk of hard coronary events among Saudi adults based on prevalence of heart disease risk factors. Journal of the Saudi Heart Association 27(3): 152-159, 2015

Prevalence of adults with no known major risk factors for coronary heart disease--behavioral risk factor surveillance system, 1992. Mmwr. Morbidity and Mortality Weekly Report 43(4): 61-3, 69, 1994

Statin is indicated to all patients with high risk of complications of coronary heart disease irrespective of the level of low density lipoprotein cholesterol. Results of HPS. Kardiologiia 42(2): 84-85, 2002

Coronary calcium predicts coronary heart disease in high risk asymptomatic adults. Journal of the American College of Cardiology 0(SPEC ISSUE): 180A, 1994

Should we measure C-reactive protein levels to ascertain the adequacy of statin therapy in patients who are at very high risk for a coronary heart disease event?. American Heart Journal 150(4): 650-651, 2005

Plasma lipids and lipoproteins and the prevalence of risk for coronary heart disease in canadian adults. Canadian Medical Association Journal 146(11): 1977-1987, 1992

Coronary calcium results predict coronary heart disease deaths in high risk asymptomatic adults. Journal of the American College of Cardiology 29(2 SUPPL A): 128A, 1997

Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999-2014. Bmc Infectious Diseases 18(1): 269-269, 2018

Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease. Polski Merkuriusz Lekarski 15(85): 42-46, 2003

Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study. Preventive Cardiology 12(2): 65-71, 2009